NewAmsterdam Pharma Company N.V. (NAMSW)

NGM

$18.80 +4.50%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History -37.3% over period

Key Metrics

Exchange

NGM

Currency

USD

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.